Hemab Therapeutics Inc. Common Stock

COAG | NASDAQ

$41.38

+$0.96 (+2.38%)

At close: Oct 30, 2026, 3:59 PM ET

$41.66

+$0.28 (+0.68%)

After-hours: Oct 30, 2026, 7:48 PM ET

TTM Period Ending	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026
Net Income	-46.84M	-22.69M
Depreciation & Amortization	n/a	73K
Stock-Based Compensation	1.32M	1.32M
Other Working Capital	n/a	427K
Other Non-Cash Items	1.35M	-663K
Deferred Income Tax	n/a	n/a
Change in Working Capital	-52K	375K
Operating Cash Flow	-44.22M	-21.58M
Capital Expenditures	n/a	-112K
Cash Acquisitions	n/a	n/a
Purchase of Investments	-148.21M	-15.74M
Sales Maturities Of Investments	25.06M	n/a
Other Investing Acitivies	-135K	n/a
Investing Cash Flow	-123.28M	-15.85M
Debt Repayment	-46K	-46K
Common Stock Repurchased	n/a	n/a
Dividend Paid	n/a	n/a
Other Financial Acitivies	-414K	-414K
Financial Cash Flow	317.12M	-460K
Net Cash Flow	149.39M	-38.11M
Free Cash Flow	-44.22M	-21.7M
Adj. Free Cash Flow	-45.54M	-23.01M
Maintenance CapEx	n/a	n/a
Growth CapEx	n/a	n/a
Owner Earnings	n/a	n/a